博瑞医药：筹划发行H股股票并在香港联交所主板上市

Group 1 - The core point of the article is that Borui Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its international strategy and enhance overseas business layout [1] - The company aims to improve its overseas financing capabilities, capital strength, and overall competitiveness through this issuance [1] - The timing and details of the issuance are still under discussion with relevant intermediaries, and the process is subject to approvals from government agencies, regulatory bodies, and the stock exchange [1]